Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oncolytic virus based cell therapy - Hospital Infantil Universitario Nino Jesus/Orgenesis

Next Previous
Drug Profile

Oncolytic virus based cell therapy - Hospital Infantil Universitario Nino Jesus/Orgenesis

Alternative Names: AloCelyvir; Celyvir; Icovir-5; Oncolytic adenovirus ICOVIR5-infected autologous mesenchymal stem cells; Oncolytic adenovirus ICOVIR5-infected autologous MSCs

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hospital Infantil Universitario Nino Jesus
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Stem cell therapies
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Diffuse intrinsic pontine glioma; Medulloblastoma

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(Combination therapy, In adolescents, In children, In infants, Newly diagnosed, In adults) in Spain (IV)
  • 28 May 2024 No recent reports of development identified for phase-I development in Medulloblastoma(In adolescents, In children, In infants, Monotherapy, Second-line therapy or greater, In adults) in Spain (IV)
  • 22 Sep 2021 Instituto de Salud Carlos III plans a phase I/II PULSE-UM trial in Uveal melanoma (Metastatic, Second-line therapy or greater) in Spain (IV, Infusion), in October 2021 (NCT05047276)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top